PAH Initial Authorization
Covered for initial pulmonary arterial hypertension (PAH) authorization when ALL applicable criteria in ONE of the product-specific pathways below are met.
ONE of the following pathways
For Adempas, Letairis, Opsumit, Opsynvi, Tracleer, Tyvaso, Tyvaso DPI, Ventavis, or Yutrepia
Pulmonary arterial hypertension is symptomatic.
Diagnosis of pulmonary arterial hypertension is confirmed by right heart catheterization.
The medication is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
Current-therapy pathway for Adempas, Letairis, Opsumit, Opsynvi, Tracleer, Tyvaso, Tyvaso DPI, Ventavis, or Yutrepia
Patient is currently receiving any therapy for the diagnosis of pulmonary arterial hypertension.
The medication is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
For Revatio oral powder for suspension, Liqrev oral suspension, or Tadliq oral suspension
ONE of the following
ALL of the following
Pulmonary arterial hypertension is symptomatic.
Diagnosis of pulmonary arterial hypertension is confirmed by right heart catheterization.
Patient is currently receiving any therapy for the diagnosis of pulmonary arterial hypertension.
Patient is unable to ingest a solid dosage form due to ONE of the following
Orenitram or Uptravi Initial Authorization
Orenitram or Uptravi is covered for initial authorization when ALL criteria in ONE of the following pathways are met.
ONE of the following pathways
Continuation-of-therapy pathway
Patient is continuing therapy with Orenitram or Uptravi.
Patient has not received a manufacturer-supplied sample at no cost in the prescriber's office or any form of assistance from a manufacturer-sponsored support program as a means to establish current use of Orenitram or Uptravi.
Patient is not taking Orenitram or Uptravi in combination with a prostanoid or prostacyclin analogue, such as epoprostenol, iloprost, or treprostinil.
The medication is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
PAH Reauthorization
Covered for reauthorization when the applicable continuation criteria are met.
Applicable product pathway
Documentation demonstrates that the patient is receiving clinical benefit from Adempas, Opsumit, Opsynvi, Letairis, Tracleer, Tyvaso, Tyvaso DPI, Ventavis, or Yutrepia therapy.
Revatio oral powder for suspension, Liqrev oral suspension, or Tadliq oral suspension
Documentation demonstrates that the patient is receiving clinical benefit from Revatio oral powder for suspension, Liqrev oral suspension, or Tadliq oral suspension therapy.
Patient remains unable to ingest a solid dosage form, such as an oral tablet, due to age, oral-motor difficulties, or dysphagia.
CTEPH Initial Authorization
Adempas is covered for initial authorization for chronic thromboembolic pulmonary hypertension (CTEPH) when the applicable CTEPH pathway is met.
ONE of the following CTEPH pathways
ALL of the following
Diagnosis of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).
The medication is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
ALL of the following
Patient is currently receiving any therapy for the diagnosis of CTEPH.
Adempas Initial Authorization for CTEPH
Adempas initial authorization for CTEPH requires ONE of the following disease/symptom or current-therapy pathways.
ONE of the following
Disease and symptom pathway
Diagnosis of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).
Adempas is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
Current-therapy pathway
Patient is currently receiving any therapy for the diagnosis of CTEPH.
Adempas Reauthorization
Covered for CTEPH reauthorization when the continuation criterion is met.
Documentation demonstrates that the patient is receiving clinical benefit from Adempas therapy.
Initial Tyvaso, Tyvaso DPI, or Yutrepia Therapy
Initial Tyvaso, Tyvaso DPI, or Yutrepia therapy is covered when ALL of the following criteria are met.
ALL of the following
Disease criteria
Diagnosis of pulmonary hypertension associated with interstitial lung disease (WHO group 3) is confirmed by right heart catheterization.
Interstitial lung disease is diagnosed based on evidence of diffuse parenchymal lung disease on computed tomography of the chest.
Pulmonary hypertension is symptomatic.
Tyvaso, Tyvaso DPI, or Yutrepia is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
Tyvaso, Tyvaso DPI, or Yutrepia Reauthorization
Covered for reauthorization when the continuation criterion is met.
Documentation demonstrates a positive clinical response to Tyvaso, Tyvaso DPI, or Yutrepia therapy, such as improved exercise ability.
These criteria apply only to the oral suspension formulations of sildenafil citrate. The intravenous formulation is not self-administered and is therefore not covered under the pharmacy benefit.
Orenitram or Uptravi may not be used in combination with a prostanoid or prostacyclin analogue, such as epoprostenol, iloprost, or treprostinil.
State mandates may apply. Federal regulatory requirements and the member-specific benefit plan may also impact coverage criteria. Other policies and utilization management programs may apply.
Brand Letairis, Liqrev oral suspension, Opsumit, Opsynvi, and Revatio oral powder for suspension are typically excluded from coverage. Tried/failed criteria may be in place; refer to plan specifics to determine exclusion status.
Endothelin receptor antagonists, including Letairis, Opsumit, Opsynvi, and Tracleer, should be used with caution in patients with liver disease. Use is not recommended in moderate to severe hepatic impairment. Tracleer product labeling includes a black box warning regarding the risk of liver injury. Prescribers should consider whether benefits outweigh the risk in WHO Class II patients, as early liver injury may preclude future use as disease progresses.
Administration of oral PDE-5 inhibitors, including Liqrev, Opsynvi, Revatio powder for oral suspension, and Tadliq, with any form of organic nitrate, regularly or intermittently, is contraindicated. Concomitant administration of oral PDE-5 inhibitors with Adempas is also contraindicated.